Summary & Overview
HCPCS J1180: Injection of Dyphylline, Up to 500 mg
HCPCS Level II code J1180 denotes an injectable dose of dyphylline (up to 500 mg), a bronchodilator formulation used in clinical settings requiring parenteral administration. Nationally, this code identifies a specific drug service line that affects drug billing, inventory management, and outpatient therapeutic workflows. It is relevant to clinicians, billing professionals, and payers because accurate use determines coverage adjudication and claims processing for injectable bronchodilator therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the medication, how the service is typically delivered, and the primary payer landscape. The publication also summarizes common modifiers associated with injectable drug services and notes where input data are not available.
This summary prepares readers to understand benchmarks and reimbursement considerations, policy and coding updates that affect injectable drug claims, and the clinical contexts where dyphylline injection is likely used. It is written for a national audience and focuses on the code definition, service setting, and payer coverage scope. Data not available in the input are identified where applicable.
Billing Code Overview
HCPCS Level II code J1180 describes an injection of dyphylline, up to 500 mg. This service is a medication administration for a bronchodilator agent delivered by injection.
Service type: Parenteral medication administration (injectable therapeutic drug)
Typical site of service: Outpatient clinic, physician office, emergency department, or other ambulatory settings where injectable medications are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related billing lines.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with acute exacerbation of chronic obstructive pulmonary disease (COPD) presents to an outpatient infusion center after failing initial inhaled bronchodilator therapy and oral methylxanthines. The physician orders an intravenous injection of dyphylline for bronchodilation and relief of airway obstruction. The clinical workflow includes verification of orders and allergies, medication preparation by pharmacy or qualified nursing staff, venous access placement if needed (peripheral intravenous line), administration of J1180 (injection, dyphylline, up to 500 mg), monitoring for cardiorespiratory response and adverse effects (tachycardia, arrhythmia, gastrointestinal upset), documentation of dose, route, time, lot number, and lot-specific drug wastage if applicable, and discharge with follow-up instructions. Billing is submitted under HCPCS Level II code J1180, with any applicable modifier to indicate circumstances such as discontinued procedure, unusual services, or payment adjustments. Typical site of service is an inpatient acute care unit, hospital outpatient department, emergency department, or freestanding infusion/ambulatory infusion center depending on acuity. Typical patient scenarios include COPD or asthma exacerbations unresponsive to first-line inhaled therapy, when an injectable methylxanthine is indicated for bronchodilation or as adjunct therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |